FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

	OMB APPROVAL							
	OMB Number: 3235-0287							
	Estimated average burden							
ı	hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  PERRY DAVID P			2. Issuer Name <b>and</b> Ticker or Trading Symbol Better Therapeutics, Inc. [ BTTX ]								Relationship neck all appl X Direct	icable)	g Per	son(s) to Iss				
(Last)	•	rst) RAPEUTICS, IN	(Middle) NC.		3. Date of Earliest Transaction (Month/Day/Year) 06/07/2023								below	Officer (give title below)  Other (below)  Executive Chairman				
548 MARKET STREET, #49404				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SAN FRANCI	ISCO C.	A	94104												filed by Mor		orting Perso n One Repo	
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							d to						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				ay/Year) Execut		A. Deeme xecution any Month/Day	Date,	Transaction Dispose Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 a		d Securit Benefic Owned	Securities For Beneficially (D)		m: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v .	Amount (A) or (D)		Price	Transa				Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Date, 7	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		oiration e	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$0.77	06/07/2023			A		15,000		(1)	06/0	06/2033	Common Stock	15,000	\$0	15,000	)	D	

## **Explanation of Responses:**

1. The stock option vests in full on the earlier of the first anniversary of the grant date and the Issuer's next annual meeting of stockholders, provided that the Reporting Person continues to serve as a director of the Issuer on such vesting date. The stock option was granted on June 7, 2023.

/s/ Mark Heinen, Attorney-in-

Fact

06/09/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.